top of page



This drug is used to treat a rare, malignant blood disease known as primary myelopibrosis.

The bodies of those affected by the disease are damaged by the production of blood cells in the bone marrow, and as a result of the creation of scar tissue in the bone marrow, blood cells form and cause damage to the body's ability to produce blood cells in the bone marrow.


One of the outcomes of the disease is an enlarged spleen condition which may manifest itself in symptoms such as abdominal pain or digestive difficulties. Studies in the field have shown that the treatment of jakabi leads to a reduction in the size of the spleen and an improvement in the symptoms of the disease in a significant proportion of patients with primary myelopibrosis.


Jakavi is also used to treat bone marrow disorders called polycythemia (PV) in which the valve produces too much red blood cells and causes the concentration of these extra cells in the blood. The action of the drug is done by blocking the action of certain enzymes in the body.


The treatment is given by swallowing tablets.

Treatment is intended for adult patients. If you have any infection (or have suffered from a recent infection), if you have tuberculosis, or hepatitis B, or if you have liver or kidney problems.


The drug is manufactured by Novartis, one of the largest and most well-known pharmaceutical companies in the world.

The company was established in 1996 by the union of two companies: Reason Gage and Sandoz. Its main base is in Basel, Switzerland, and has many branches throughout the world.


The company is responsible for the development of quite a few well-known drugs, such as Ritalin and Waltran, and is a major and important part of the global pharmaceutical market.

  • Contents

    14 tablets in one strip and 4 strips in total (total 56 tablets per box).

  • Active Ingredient

    Ruxolitinib Phosphate

bottom of page